*Eastern Standard Time EST

8:30 am Morning Registration & Virtual Networking

JAK Inhibitor Overview: Current Landscape & Challenges

8:50 am Chair’s Opening Remarks

  • Massimo Gadina Director & Chief of Translational Immunology Section, Science & Technology, NIAMS/NIH

9:00 am Where do JAK Inhibitors Fit in the Landscape of Anti-Inflammatory Therapeutics? Current & Future Considerations

Synopsis

  • Touching upon the position and properties of JAKis when focussing on new inflammatory targets moving into clinical investigation
  • Understanding what separated JAKi from other biologics small molecule treatments
  • Analyzing the attempts to quantify and qualify the empiricism of JAKi in a multitude of therapies

9:25 am The Evolving Landscape of JAK Inhibitors: Revisiting Selectivity, Delivery & Safety

  • Paul Smith Senior Director Pharmacology (non-oncology), Incyte

Synopsis

  • Pharma’s drive for exquisite biochemical selectivity for inflammatory diseases
  • Oral and topical JAK inhibitors in clinical development
  • The emerging safety landscape (hematology, infection, cardiovascular & oncology)

9:50 am An Overview of JAKi in Rheumotology

  • Massimo Gadina Director & Chief of Translational Immunology Section, Science & Technology, NIAMS/NIH

Synopsis

  • Historical overview of how JAK inhibitors were developed.
  • Review of first-generation pan-JAK inhibitors and their current clinical application
  • JAK-selective, second-generation JAK inhibitors: what is there already and what is arriving.
  • The effect of JAK inhibitors on circulating immune cell

10:15 am Building Confidence with Photo Documentation

  • Mira Patel Clinical Team Leader, Canfield Scientific

Synopsis

  • Providing quality standardized images demonstrate treatment efficacy.
  • Showing how photo documentation builds confidence for Regulatory Agency, Investigators, Patients and Investors
  • Detailing quantitative measurements for endpoint data and describing the role of investigator qualifications for assessments

10:25 am Speaker Q&A panel

  • Luke O’Neil Chair of Biochemistry, Trinity College Dublin
  • Paul Smith Senior Director Pharmacology (non-oncology), Incyte
  • Massimo Gadina Director & Chief of Translational Immunology Section, Science & Technology, NIAMS/NIH
  • Mira Patel Clinical Team Leader, Canfield Scientific
  • Doug Canfield President, Canfield Scientific

10:40 am Defining Value in Various Clinical Branches of Medicine

  • Brett King Associate Professor of Dermatology, Yale University School of Medicine
  • Vibeke Strand Adjunct Professor - Clinical, Division, Immunology & Rheumatology, Stanford University School of Medicine
  • John Mascarenhas Associate Professor of Medicine; Myeloproliferative Disorders Program, Mount Sinai School of Medicine

Synopsis

  • Providing an update on current and expected JAKis within each panellist’s specialty
  • Comparing the value and challenges of JAKis between disciplines to highlight potential in future clinical practice
  • Collaboratively accenting current and future therapeutic opportunities where unmet medical need exist

11:30 am Virtual Speed Networking

11:50 am Coffee Break

JAK Inhibitor’s MOA & Immunological Success

12:10 pm A Prime Target for Viral Immune Evasion: JAK/STAT Pathway

Synopsis

  • Exploring mechanisms by which several viruses (HIV, RSV, HCV) target the anti-viral Type 1 IFN pathway
  • Depicting how Coronaviruses target JAK/STAT signalling

12:35 pm Cytokine Storm Implicates Use of Baricitinib in Hospitalized amCOVID-19 Patients

  • Gary Krishnan Senior Research Fellow Medical, Eli Lilly & Company

Synopsis

  • Narrating Lilly’s fast- approval process for Baracitinib for pandemic application
  • Addressing the MOA of a cytokine storm and effects this provides on JAKi use
  • Potential anti-host anti-viral mechanism for Baricitinib and potential implications

1:00 pm JAK/STAT Mutations in Humans – Biochemistry, Immunology & Epigenetics of JAK inhibition

  • Dusan Bogunovic Associate Professor | Director- Center for Inborn Errors of Immunity, Icahn School of Medicine at Mount Sinai

Synopsis

  • Different mutations different outcomes
  • Drug specificity based on genetic variant
  • Single cell analyses of JAK inhibitor effectiveness
  • Epigenetics of JAK biology

1:25 pm Speaker Q&A panel

  • Nigel Stevenson Assistant Professor Immunology, Trinity College Dublin
  • Gary Krishnan Senior Research Fellow Medical, Eli Lilly & Company
  • Dusan Bogunovic Associate Professor | Director- Center for Inborn Errors of Immunity, Icahn School of Medicine at Mount Sinai

1:40 pm Lunch

Rethinking JAK Inhibitor’s Combinational & Endpoint Opportunities

2:40 pm Panel: Past, Present & Future Combinational Opportunities with JAKis

  • William Damsky Assistant Professor in Dermatology & Dermatopathology, Yale School of Medicine
  • Gary Krishnan Senior Research Fellow Medical, Eli Lilly & Company
  • Ruben Mesa Executive Director, Mays Cancer Center, UT Health San Antonio MD Anderson
  • Iain Stuart Chief Scientific Officer, VYNE Therapeutics

Synopsis

  • Addressing the current dearth in certain disease profiles and speculating the use of combinational approaches for JAKi
  • Highlighting the benefit of combinational approaches for targeted therapeutic treatments
  • Discussing the current and future drug spectrum to highlight particular opportunities

3:20 pm The Problem of Pain in Inflammatory Disease; What is the Role for JAK Inhibition?

  • Peter Taylor Professorial Fellow, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMs)

Synopsis

  • Investigating the quick, efficacious MOA of JAKi in the pain response
  • Detailing the limitations to current measures of outcome in rheumatic disease

3:45 pm Patient Reported Outcomes with JAKi’s in Rheumatoid & Psoratic Arthritis

  • Vibeke Strand Adjunct Professor - Clinical, Division, Immunology & Rheumatology, Stanford University School of Medicine

Synopsis

  • Detailing how PROs are an important clinical endpoint for patients
  • Presenting the results of JAKi therapy in RA across DMARD-IR, bDMARDIR and DMARD-naive RA patients; how they correspond w/ clinical endpoints
  • Detailing how these results are clinically meaningful and help patients feel and function as if they no longer have arthritis

4:10 pm Afternoon break

Addressing Applicational Advantages

4:50 pm Topical JAK Inhibitor Development – the Promise & the Challenges

  • Paul Barclay Vice President, Global Program Head, Global Development , Leo Pharma

Synopsis

  • Exploring how efficacy compares with oral JAKs
  • Recalling what methods are available to assess skin penetration and target occupancy
  • Detailing whether lower systemic exposure leads to a better safety profile
  • Sharing the regulatory challenges

5:15 pm Developing inhaled JAKs to Address Unmet Needs in Respiratory Disease

  • Frazer Morgan Chief Development Officer & Co-Founder, Kinaset Therapeutics, Inc

Synopsis

  • Detailing the mechanism of action for JAK inhibition in asthma
  • Providing key challenges in inhaled JAK development
  • Describing a KN-002 program overview

5:40 pm Closing Q&A Panel

  • Frazer Morgan Chief Development Officer & Co-Founder, Kinaset Therapeutics, Inc
  • Paul Barclay Vice President, Global Program Head, Global Development , Leo Pharma

6:00 pm Chair’s closing remarks

  • Massimo Gadina Director & Chief of Translational Immunology Section, Science & Technology, NIAMS/NIH